Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul 4;144(1):1-2.
doi: 10.1182/blood.2024024942.

Mavorixafor: a new hope for WHIM syndrome

Christoph B Geier  1
Affiliations
Free article
Editorial

Mavorixafor: a new hope for WHIM syndrome

Christoph B Geier. Blood. .
Free article
No abstract available

PubMed Disclaimer

Comment on

  • A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.
    Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, Dale D, Deyà-Martínez À, Dickerson KE, Ezra N, Hasle H, Kang HJ, Kiani-Alikhan S, Kuijpers TW, Kulagin A, Langguth D, Levin C, Neth O, Olbrich P, Peake J, Rodina Y, Rutten CE, Shcherbina A, Tarrant TK, Vossen MG, Wysocki CA, Belschner A, Bridger GJ, Chen K, Dubuc S, Hu Y, Jiang H, Li S, MacLeod R, Stewart M, Taveras AG, Yan T, Donadieu J. Badolato R, et al. Blood. 2024 Jul 4;144(1):35-45. doi: 10.1182/blood.2023022658. Blood. 2024. PMID: 38643510 Free PMC article. Clinical Trial.

Similar articles

  • Mavorixafor: a CXCR4 antagonist for WHIM syndrome.
    Chen C, Xu B, Li W, Chen J, He Z, Zhou J. Chen C, et al. Immunopharmacol Immunotoxicol. 2025 Jun;47(3):385-391. doi: 10.1080/08923973.2025.2491551. Epub 2025 Apr 14. Immunopharmacol Immunotoxicol. 2025. PMID: 40223492 Review.
  • A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.
    Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, Dale D, Deyà-Martínez À, Dickerson KE, Ezra N, Hasle H, Kang HJ, Kiani-Alikhan S, Kuijpers TW, Kulagin A, Langguth D, Levin C, Neth O, Olbrich P, Peake J, Rodina Y, Rutten CE, Shcherbina A, Tarrant TK, Vossen MG, Wysocki CA, Belschner A, Bridger GJ, Chen K, Dubuc S, Hu Y, Jiang H, Li S, MacLeod R, Stewart M, Taveras AG, Yan T, Donadieu J. Badolato R, et al. Blood. 2024 Jul 4;144(1):35-45. doi: 10.1182/blood.2023022658. Blood. 2024. PMID: 38643510 Free PMC article. Clinical Trial.
  • Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
    Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, Gorelick KJ, Ebrahim T, Garg V, Tang W, Jiang H, Skerlj R, Beaussant Cohen S. Dale DC, et al. Blood. 2020 Dec 24;136(26):2994-3003. doi: 10.1182/blood.2020007197. Blood. 2020. PMID: 32870250 Free PMC article. Clinical Trial.
  • A WHIM satisfactorily addressed.
    Broxmeyer HE. Broxmeyer HE. Blood. 2014 Apr 10;123(15):2286-8. doi: 10.1182/blood-2014-02-557579. Blood. 2014. PMID: 24723677
  • Mavorixafor: First Approval.
    Hoy SM. Hoy SM. Drugs. 2024 Aug;84(8):969-975. doi: 10.1007/s40265-024-02063-y. Epub 2024 Jul 15. Drugs. 2024. PMID: 39004659 Review.
See all similar articles

Cited by

References

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources